Algorithme Pharma USA has its First Studies Underway

LAVAL, QC, Canada (Feb. 10, 2015) — Last October, Altasciences expanded into the United States with the opening of Algorithme Pharma USA, in Fargo, North Dakota. Today, we are pleased to announce that our first studies were initiated and completed in January, just 91 days from the US contract being signed, and despite the holiday hustle. These are exciting times for both Algorithme Pharma USA and Algorithme Pharma, Montreal, Canada, who have been working side-by-side to upgrade the newly acquired facility, hire and train expert staff, recruit study participants, incorporate all standard operating procedures, and implement an IT infrastructure to allow both sites to work seamlessly. Yes, all in just three months. Dr. Jim Carlson, President and Chief Executive Officer, Algorithme Pharma USA, had this to say once the first dosing was completed: “Everybody, and I mean everybody, is pitching in and helping out. I have never seen a faster, yet complete, integration of two companies… and such respect between colleagues. These experienced staff are focused and dedicated…. Just magnificent!” “From a business development perspective, the announcement of the reopening of the facility formerly managed by PRACs, under the direction of Dr. Jim Carlson was well received by the client community. Algorithme Pharma USA provides an excellent U.S. based facility to perform quality bioequivalence work.” stated Marie-Hélène Raigneau, Executive Director, Business Development and Marketing. About Altasciences Altasciences, owned by Kilmer Capital Partners, owns Algorithme Pharma, Algorithme Pharma USA and Vince and Associates Clinical Research. All organizations operate with a common mission, to provide the best quality early stage clinical development services to an international customer base of pharmaceutical, biotechnology and generic companies with a focus on customer service. Altasciences, through its group of companies, provides comprehensive early stage clinical drug development services in Phase I/ IIa, including the necessary support services in this critical stage of drug development. Leveraging the extensive expertise and capabilities within the group, the strategy is to maintain the core competencies and identity of each company and ensure that they benefit from the value of being part of a common larger organization focused on excellence in customer service, operating under the ALTASCIENCES banner. About Kilmer Capital Partners Kilmer Capital Partners is a leader in making private equity investments in mid-sized businesses undergoing periods of rapid growth, significant change or ownership transition. The Principals of Kilmer Capital have the strategic, operational, acquisition and financial expertise and experience to assist management teams in achieving their strategic visions. More Information Altasciences Marie-Helene Raigneau Executive Director, Business Development and Marketing [email protected] |

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.